PATENT CLAIM ANALYSIS

Application Number: 16119430
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-08
Patent Classification: ["514", "249000"]

Abstract:
This invention applies to the field of medicine, namely to endocrinology, and intended for the treatment of type 1 diabetes mellitus. The invention proposes a combination, containing a Dipeptidyl peptidase-4 (DPP-4) inhibitors, a proton pump inhibitors (PPI), and gamma-aminobutyric acid or a gamma-aminobutyric acid receptor agonists. This unique combination of medications and specific dosage of drugs leads to the regeneration (recovery) of the β-cells of the pancreas, which is presented by a dramatic reduction of insulin requirements up to a total insulin discontinuation in some persons.

Claim (Index 2):
A combination according to  claim 1 , characterized in that the medication of the DPP-4 inhibitor group is sitagliptin, wherein the medication of the PPI group is omeprazole.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 96.0
- Lexical Diversity: 1.60317
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15235575', '12673327', '14071976', '15983249', '13511771']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7198792973434235
- 35 USC 102 Novelty (BERT): 0.4765369077136956
- Combined Prediction Score: 0.6955450583804508
- Mean Citation Score: 193.499038
- Max Citation Score: 197.24313
- Similarity Product: 158.42471925336957

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test